世界范围内9～26岁女性对HPV的认知现状及预防性HPV疫苗的应用现况

HPV-related Knowledge and Application of HPV Vaccines Among Female Aged 9 to 26 Worldwide

持续感染人乳头状瘤病毒(human papilloma virus,HPV)是宫颈癌发生的必要病因。目前HPV疫苗作为宫颈癌的一级预防措施正在全球范围内很多国家和地区实施。世界卫生组织(WHO)推荐9岁以上女性接种HPV疫苗,而9~26岁被认为是最佳接种年龄,很多国家也对接种年龄界定在9~26岁之间。2016年7月18日,HPV二价疫苗(HPV16和18型)希瑞适誖(Cervarix誖)获得中国食品药品监督管理局(CFDA)的上市许可,它适用于9~25岁女性,采用3剂免疫接种程序。而该人群对于HPV的认知以及疫苗接种的组织形式是影响HPV疫苗计划成功实施的重要因素。全文综述了国内外9~26岁女性关于HPV认知的现状及HPV疫苗应用现况,为将来在我国适龄人群中成功推广和接种预防性HPV疫苗提供参考依据。

Cervical cancer is one of the most common malignancies among females worldwide,with persistent HPV infection as its necessary cause. Prophylactic HPV vaccines have been licensed and applied in many countries and regions worldwide as a primary prevention for cervical cancer.The World Health Organization（WHO） recommends that females aged ≥9 years old should be vaccinated with the HPV vaccine. Many countries recommend that the best age to be vaccinated is between the ages of 9~26 years old. The bivalent（HPV16 and 18） vaccine（Cervarix 誖） was approved by China Food and Drug Administration（CFDA） On July 18,2016,and it was authorized to be used on women aged 9~25 years with three doses of immunization. However,the successful implication of HPV vaccination is related to HPV knowledge among females of this age group and the organization of HPV vaccination. Thus,this article reviewed the overall knowledge of HPV among9 to 26 year-old females worldwide and the application of the HPV vaccines, which aims to provide necessary information to help a successful promotion and implementation of HPV vaccines a-mong Chinese female of appropriate age group in future.